Zelluna ASA (ZLNA.OL), a company focused on allogeneic off-the-shelf T Cell Receptor-based Natural Killer or TCR-NK cell therapies for the treatment of solid cancers, Monday announced a collaboration with Etcembly Ltd., a biotechnology company that uses artificial intelligence and machine learning to analyse large amounts of data on immune receptors through its proprietary platform, EMLy.
The collaboration will focus on engineering high-affinity, tumour-specific TCRs targeting KKLC1, a validated cancer antigen expressed in multiple difficult-to-treat solid tumours.
Following the news, ZLNA.OL is up 3.45%, at NOK 16.13.
Etcembly's EMLy enables the design and engineering of optimised T cell receptors through computational modelling before they are tested in the laboratory.
The partnership is built on Zelluna's lead T cell receptor candidate, ZI-MA4-1, designed to recognise the cancer antigen MAGE-A4, found in many solid cancers, including lung, ovarian, head and neck cancers, and sarcomas.
The engineered receptors will be fully owned by Zelluna and developed for use within Zelluna's proprietary TCR-NK platform.
Currently, In-vitro data demonstrating safety, specificity, and functional activity are expected in the fourth quarter of 2026.
ZLNA.OL has traded between NOK 8.20 and NOK 22.50 in the prior year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.